Nurtec (Rimegepant) Dosing Based on Headache Days
Nurtec can be prescribed for patients with up to 14 headache days per month (episodic migraine), with acute dosing limited to a maximum of 18 doses per 30-day period, and preventive dosing administered as 75 mg every other day. 1
Maximum Headache Days for Prescribing
The FDA-approved indication and recent ACP guidelines define episodic migraine as 1 to 14 headache days per month 2. Nurtec is specifically indicated for this population. Patients with ≥15 headache days per month meet criteria for chronic migraine, which falls outside the studied and approved population for rimegepant.
Dosing Regimens
Acute Treatment Dosing
- Dose: 75 mg orally as needed
- Maximum frequency: One dose per 24-hour period
- Safety limit: No more than 18 doses in a 30-day period 1
This 18-dose monthly limit is critical—the safety of exceeding this threshold has not been established. This constraint effectively means patients should not use acute dosing on more than 18 days per month.
Preventive Treatment Dosing
- Dose: 75 mg every other day (approximately 15 doses per month) 1
- This regimen demonstrated significant reduction in monthly migraine days (mean reduction of 0.91-1.49 days) with improved quality of life scores 3, 4, 5
Critical Medication Overuse Considerations
Be vigilant about medication overuse headache (MOH), which develops when acute medications are used ≥10 days per month for triptans or gepants 6. The 18-dose monthly safety limit for Nurtec acute treatment approaches this MOH threshold, making it essential to:
- Monitor monthly usage patterns closely
- Consider transitioning to preventive therapy if patients consistently need acute treatment >10 days/month
- Educate patients that MOH is defined as headache occurring ≥15 days/month for ≥3 months due to medication overuse
Treatment Algorithm
For patients with 4-8 moderate-to-severe migraine days/month:
- Start with acute treatment (75 mg as needed, maximum 18 doses/month)
- If inadequate response or frequent use (approaching 10 days/month), add preventive therapy
For patients with 9-14 migraine days/month:
- Initiate preventive therapy (75 mg every other day) as first-line 2
- Can add acute dosing on non-scheduled days if breakthrough attacks occur (maximum one dose per calendar day total) 1, 5
For patients with <4 migraine days/month:
- Acute treatment only is appropriate
- Reserve gepants like Nurtec for patients who fail or cannot tolerate triptan + NSAID combination therapy 6
Positioning in Treatment Hierarchy
According to the 2025 ACP guidelines, rimegepant is not first-line for acute treatment. The recommended sequence is 6:
- Start with NSAID or acetaminophen
- If inadequate response, add a triptan to NSAID/acetaminophen
- Only consider rimegepant if patients do not tolerate or have inadequate response to triptan + NSAID/acetaminophen combination
This positioning reflects that combination therapy (triptan + NSAID) demonstrates superior efficacy compared to rimegepant monotherapy for pain freedom and sustained relief 6.
Drug Interactions Affecting Dosing
Avoid another dose within 48 hours when rimegepant is co-administered with 1:
- Moderate CYP3A4 inhibitors (e.g., fluconazole, verapamil)
- Potent P-glycoprotein inhibitors (e.g., cyclosporine, quinidine)
Completely avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) or strong/moderate CYP3A inducers (e.g., rifampin, carbamazepine), as these may lead to loss of efficacy.
Safety Profile
Long-term data (up to 52 weeks) demonstrates favorable tolerability 7, 5:
- Most common adverse events: nasopharyngitis (6.8-25.1%), upper respiratory infection (8.8%), nausea (1-2%)
- No signal of hepatotoxicity in clinical trials
- Serious adverse events rare (0.6-0.9%)
- Discontinuation due to adverse events: 1.3%
Monitor for hypertension, as CGRP antagonists can cause new-onset or worsening hypertension, particularly in patients with pre-existing risk factors 1.